This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
McKesson (MCK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
McKesson (MCK) closed the most recent trading day at $336.20, moving +0.07% from the previous trading session.
Here's Why You Should Retain McKesson (MCK) Stock Right Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Nevro's (NVRO) Latest Launch to Customize Chronic Pain Treatment
by Zacks Equity Research
Nevro's (NVRO) Senza HFX iQ SCS system is expected to treat individual patients per their particular treatment requirements.
Here's Why You Should Retain Catalent (CTLT) Stock for Now
by Zacks Equity Research
Catalent's (CTLT) product and service launches and a slew of strategic deals raise optimism about the stock.
Cardinal Health's (CAH) New Tie-Up to Boost Patient Outcomes
by Zacks Equity Research
Cardinal Health's (CAH) latest partnership is expected to improve patients' healthcare journey by offering a more integrated experience that connects all sites of care.
Three Reasons to Add BD (BDX) Stock to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and product launches.
All You Need to Know About McKesson (MCK) Rating Upgrade to Buy
by Zacks Equity Research
McKesson (MCK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here's Why You Should Retain Surmodics (SRDX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
Walgreens Boots (WBA) Benefits From New Launches Amid FX Woes
by Zacks Equity Research
Walgreens Boots' (WBA) comparable pharmacy sales decline, reflecting lower demand for COVID-19 services.
Are Investors Undervaluing Cardinal Health (CAH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cooper Companies (COO) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Cooper Companies' (COO) first-quarter fiscal 2023 revenues reflect a solid segmental performance despite a year-over-year decline in earnings.
NextGen (NXGN) Behavioral Health Suite Adopted by Compass Health
by Zacks Equity Research
NextGen's (NXGN) Behavioral Health Suite is expected to aid Compass Health in improving its workflow.
Zacks.com featured highlights Hershey's, ParkerHannifin, Interpublic Group, Microchip Technology and McKesson
by Zacks Equity Research
Hershey's, ParkerHannifin, Interpublic Group, Microchip Technology and McKesson have been highlighted in this Screen of The Week article.
Veeva Systems (VEEV) Q4 Earnings Beat, Margins Decline
by Zacks Equity Research
Veeva Systems' (VEEV) Q4 results reflect impressive performances by both segments.
National Vision (EYE) Q4 Revenues Miss Mark, Margins Down
by Zacks Equity Research
National Vision (EYE) is facing a challenging macroeconomic environment, which negatively impacted its performance in the fourth quarter of 2022.
Patterson Companies (PDCO) Q3 Earnings Beat, Sales Hurt by FX
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal third-quarter 2023 results are negatively impacted by unfavorable currency movements.
5 Smart Beta Dividend Stocks to Buy Now for Steady Gains
by Sweta Killa
Hershey (HSY), ParkerHannifin (PH), The Interpublic Group (IPG), Microchip Technology (MCHP), and McKesson (MCK) could be solid choices for your portfolio amid rising yields.
Myriad Genetics (MYGN) Q4 Earnings Top, Gross Margin Falls
by Zacks Equity Research
Myriad Genetics (MYGN) hereditary cancer testing volume registered strong growth in the fourth quarter. GeneSight comes up with yet another strong performance.
After Plunging -7.62% in 4 Weeks, Here's Why the Trend Might Reverse for McKesson (MCK)
by Zacks Equity Research
The heavy selling pressure might have exhausted for McKesson (MCK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Masimo (MASI) Q4 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Masimo's (MASI) robust product shipments and continued strength in its healthcare business drive its Q4 sales.
Inari Medical (NARI) Q4 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Inari Medical's (NARI) fourth-quarter results benefit from significant progress made across all its growth drivers.
DENTSPLY SIRONA (XRAY) Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) Q4 earnings and revenues decline year over year due to unfavorable foreign currency movement and soft demand across all geographical segments.
PerkinElmer's (PKI) Latest Launch to Boost Research Workflows
by Zacks Equity Research
PerkinElmer's (PKI) latest launch is expected to provide increased assay flexibility to researchers.
Reasons to Add Quest Diagnostics (DGX) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Quest Diagnostics (DGX) on its accelerated growth strategy and improvements in base volumes.
BD's (BDX) New FDA Approval to Improve Cervical Cancer Testing
by Zacks Equity Research
BD's (BDX) receipt of the latest FDA approval is likely to improve the detection and prevention of cervical cancer.